Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis
Open accessPublished version of a preprint
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Abstract Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAFV600E/K-mutant melanoma. Efficacy of BRAFi + MEKi associates with cancer cell death and alterations in the tumor immune microenvironment; however, the links are poorly understood. We show that BRAFi + MEKi caused durable melanoma regression in an immune-mediated manner. BRAFi + MEKi treatment promoted cleavage of gasdermin E (GSDME) and release of HMGB1, markers of pyroptotic cell death. GSDME-deficient melanoma showed defective HMGB1 release, reduced tumor-associated T cell and activated dendritic cell infiltrates in response to BRAFi + MEKi, and more frequent tumor regrowth after drug removal. Importantly, BRAFi + MEKi–resistant disease lacked pyroptosis markers and showed decreased intratumoral T-cell infiltration but was sensitive to pyroptosis-inducing chemotherapy. These data implicate BRAFi + MEKi–induced pyroptosis in antitumor immune responses and highlight new therapeutic strategies for resistant melanoma. Significance: Targeted inhibitors and immune checkpoint agents have advanced the care of patients with melanoma; however, detailed knowledge of the intersection between these two research areas is lacking. We describe a molecular mechanism of targeted inhibitor regulation of an immune-stimulatory form of cell death and provide a proof-of-principle salvage therapy concept for inhibitor-resistant melanoma. See related commentary by Smalley, p. 176. This article is highlighted in the In This Issue feature, p. 161
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“induction of ICD (Box 1) (Erkes et al., 2020; Wang et al., 2020a)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Erkes et al., 2020
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T., Mok, S., Cass, A., Haynes, N. M., Kinross, K., Yagita, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 269
RetractedGSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680 · cited 3×
“We confirmed the ability of etoposide and also tested doxorubicin, a known chemotherapeutic inducer of pyroptosis, for ability to cause GSDME cleavage in CRT cell lines (31,32,34).”
BackgroundSelf-citationToll-like receptors: critical proteins linking innate and acquired immunity
Akira, S., Takeda, K., & Kaisho, T. (2001) · Nature Immunology · doi:10.1038/90609 · Cited by 4,777 · cited 1×
“Released HMGB1 is known to promote inflammation through its binding to toll-like receptor 4 on dendritic cells (45, 46).”
BackgroundRelease of chromatin protein HMGB1 by necrotic cells triggers inflammation
Scaffidi, P., Misteli, T., & Bianchi, M. E. (2002) · Nature · doi:10.1038/nature00858 · Cited by 4,221 · cited 1×
“Released HMGB1 is known to promote inflammation through its binding to toll-like receptor 4 on dendritic cells (45, 46).”
BackgroundClassification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., et al. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.150 · Cited by 3,399
Self-citationInflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
Liu, X., Zhang, Z., Ruan, J., Pan, Y., Magupalli, V. G., Wu, H., & Lieberman, J. (2016) · Nature · doi:10.1038/nature18629 · Cited by 3,202 · cited 1×
“It has recently been shown that the intrinsic apoptotic pathway intersects with a distinct form of cell death termed pyroptosis that is gasderminmediated and involves pore-based release of immune stimulatory factors (28-31).”
BackgroundChemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
Wang, Y., Gao, W., Shi, X., Ding, J., Liu, W., He, H., Wang, K., & Shao, F. (2017) · Nature · doi:10.1038/nature22393 · Cited by 3,199 · cited 1×
“This pore formation causes the release of immune stimulants, including HMGB1, which are able to induce dendritic cell (DC) activation and, in turn, propagate antitumor T-cell activity (32, 33, 35).”
Background
Cited by
Items 301–400 of 520
BAP1 Loss Affords Lipotoxicity Resistance in Uveal Melanoma
Cunanan, C. J., Amirfallah, A., Sanders, A., Gallant, K. C., Cavallo, M. R., Homer, E. M., Naggar, O. S. E., Farnan, J. K., Romano, G., Hope, J. L., et al. (2025) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.70021 · Cited by 9
Self-citationZhang, G., Luo, Y., Dong, W., & Zhong, W. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/8233840 · Cited by 9
“Gasdermin E-dependent pyroptosis might be indispensable in mediating the immunotherapy response of BRAF mutant melanoma [8].”
BackgroundXu, J., Chen, K., Wei, Z., Wu, Z., Huang, X., Cai, M., Yuan, K., Huang, P., Zhang, J., & Wang, S. (2022) · Journal of Oncology · doi:10.1155/2022/3102743 · Cited by 9
“Pyroptosis occurs in pathogen-infected cells, causing an inflammatory reaction and cell lysis within the host body [23].”
BackgroundPyroptosis Modulators: New Insights of Gasdermins in Health and Disease
Allali-Bouamara, I., Marrero, A. D., Quesada, A. R., Martínez-Poveda, B., & Medina, M. Á. (2023) · Antioxidants · doi:10.3390/antiox12081551 · Cited by 9
“Combination of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) BRAF V600E/K-mutant melanoma Increased GSDME-mediated pyroptosis related to ERK1/2 pathway inhibition Human and syngeneic mouse melanoma models [103]”
BackgroundZhao, X. Y., Chen, C., Han, W., Liang, M., Cheng, Y., Chen, Y., Pang, D., Lei, H., Feng, X., Cao, S., et al. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18094 · Cited by 9
Deng, D., Liu, F., Liu, Z., Wu, Z., He, Y., Zhang, C., Zu, X., Ou, Z., & Wang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.965469 · Cited by 9
“that pyroptotic cell death of cancer cells promotes dendritic cell activation and T cell infiltration and enhances anti-tumor immune responses by releasing high mobility group protein B1 (42).”
BackgroundZhang, T., Zhang, C., Fu, Z., & Gao, Q. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091768 · Cited by 9
“It has been proved that the immunoregulatory effects induced by combinatorial therapy are vital to tumor shrinkage [22].”
BackgroundTan, X., Yang, J., Li, Y., Wan, K., Feng, S., Jing, X., Xie, Z., Zhang, L., & Li, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1616715 · Cited by 8
“Another research showed that chemotherapeutic agents in gastric cancer and small-molecule kinase inhibitors in lung cancer and melanoma cells also induced pyroptosis through the GSDME/ caspase-3 pathway to contribute signi fi cantly on tumor suppression (47).”
Xu, T., Gu, H., Zhang, C., Zhang, W., Liang, X., & Cheng, X. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.843538 · Cited by 8
Gasdermin-mediated pyroptosis confers anticancer immunity
Lin, W., Lin, B., Zhou, Q., & Teng, L. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008162 · Cited by 8
“17 18 CHALLENGES A significant challenge in the development of cell death-based anticancer strategies is the presence of methylations, mutations or downregulation in the expression of GSDM in many tumors.”
BackgroundSphingolipid metabolism and regulated cell death in malignant melanoma
Yan, K., Zhang, W., Song, H., & Xu, X. (2024) · APOPTOSIS · doi:10.1007/s10495-024-02002-y · Cited by 8
“The combina - tion use of BRAFi and MEKi can promote the cleavage of GSDME, the release of high mobility group box 1 protein (HMGB1), and increased infiltration of tumor-associated T cells in MM cells, thereby inducing pyroptosis [81 ].”
Overcoming multiple barriers to deliver photo-gene system for glioma-targeted combined therapy
Qin, Y., Yang, L., Yang, Y., Gao, W., Aihemaiti, K., Jiang, G., Huang, R., Khan, H., & Huang, R. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.024 · Cited by 8
Yuan, S.-M., Chen, X., Qu, Y.-Q., & Zhang, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-75650-4 · Cited by 8
“Moreover, pyroptosis may play key role in the regulation of tumor microenvironment (TME) 15–17 .”
BackgroundEnßle, S., Sax, A., May, P., Khawanky, N. E., Soliman, N., Perl, M., Enssle, J. C., Krey, K., Ruland, J., Pichlmair, A., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2504244 · Cited by 8
“22,23 26 The pyroptosis gene set has been described previously, 27 the RIG-I-like receptor signaling pathway gene set was from the Kyoto encyclopedia of genes and genomes (KEGG).”
Li, X., Lu, F., Zhou, J., Li, X., Li, Y., Ye, W., Li, J., Yang, L., Tang, S. J., Zhou, Y., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07839-y · Cited by 8
“Meanwhile, the combination of BRAF inhibitor and MEK inhibitor was shown to induce GSDME-dependent pyroptosis in mouse melanoma cells and increase T cell in fi ltration [51].”
Li, Y., Li, Y., Zhang, X., Duan, X., Feng, H., Yu, Z., & Gao, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.986827 · Cited by 8
“Moreover, HMGB1 functioned as the executor of pyroptotic cell death to participate in the regulation of tumor immune microenvironment via the inhibition of mutant BRAF and MEK (40).”
BackgroundXu, Z., Li, Z. Z., Deng, Z., Ding, C., Wu, J., Zhang, C., Wei, H., He, T., Long, L., Tang, L., et al. (2026) · Nature Cell Biology · doi:10.1038/s41556-026-01902-2 · Cited by 7
Kinase Inhibitors’ Effects on Innate Immunity in Solid Cancers
Peng, C., Rabold, K., Mulder, W. J. M., Jaeger, M., & Netea-Maier, R. T. (2021) · Cancers · doi:10.3390/cancers13225695 · Cited by 7
“Indeed, in an immunocompetent murine model, the BRAF–MEK inhibitor treatment increased the expression of multiple immunostimulatory molecules, including HMGB1, calreticulin, and IL-1α, from melanoma cells, which led to increased major histocompatibility complex (MHC) -II expression on the tumor-resident DCs [38].”
BackgroundInfluentialDong, L., Choi, H., Budhu, S., Schulze, I., Verma, S., Mangarin, L. M. B., Navarro, V. E., Mehanna, N., Khan, J. F., Venkatesh, D., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0729 · Cited by 7
Zhang, J., Dong, H., Liang, L., Hu, L., Chen, J., Li, W., Liu, J., Su, Y., Shi, M., Feng, Y., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03106-1 · Cited by 7
“These results suggest that cobimetinib promotes MHC-I expression by enhancing NLRC5 expression.”
Gao, J., Wang, D., Yang, Q., Tang, M., Du, J., He, L., & Liu, W. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1131402 · Cited by 7
“BRAF mutations could indirectly modulate the tumor immune microenvironment by modulating the pyroptosis-related signaling pathways (Erkes et al., 2020).”
BackgroundZhang, J., You, X., Kang, D., & Zhou, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.932786 · Cited by 7
“Some investigations have documented that pyroptosis’ powerful proinflammatory activity may influence tumor immune microenvironment modulation (35).”
BackgroundPredictive biomarkers for response to trametinib in non-small cell lung cancer
Parekh, P. R., Botting, G. M., Thurber, D. B., Boruszczak, M., Murphy, W., & Bertenshaw, G. P. (2022) · Tumor Biology · doi:10.3233/tub-220009 · Cited by 7
“We cannot rule out the possibility that trametinib may induce necroptosis [28].”
BackgroundDeterminants for Antitumor and Protumor Effects of Programmed Cell Death
Workenhe, S. T., Inkol, J. M., Westerveld, M. J., Verburg, S. G., Worfolk, S. M., Walsh, S. R., & Kallio, K. L. F. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0321 · Cited by 7
“In addition to these noncell autonomous effects, oncogenic pathways involving oncogenes and tumor suppressors can also interfere with the cancers own cell death machinery to either provide a proliferative advantage or allow escape from immune-mediated attack (100, 116 – 121).”
BackgroundChou, M.-Y., & Yang, M. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102353 · Cited by 6
“…effects, including upregulation of tumor associated antigens and improved antigen presentation [50 – 54], induction of immunogenic cell death [55], secretion of TH1 cytokines such as CXCL9 and CXCL10 [53] and downregulation of immunosuppressive factors, including IL8, VEGFA, and the MDSC…”
Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma
Tiago, M., Purwin, T. J., Stefanski, C. D., da Silva, R. O., Fane, M. E., Chhabra, Y., Haj, J. I., Teh, J. L. F., Kadamb, R., Cai, W., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci178446 · Cited by 6
“Additionally, as BRAFi + MEKi treatment induces cell death (35), we tested whether NR2F1 overexpression affected cell death by measuring propidium iodide (PI) uptake via real-time IncuCyte analysis.”
Self-citationPyroptosis Modulates Multiple Immune Cell Populations in Targeted Therapy–Treated Melanoma
Wilski, N. A., Erkes, D. A., Purwin, T. J., Melissaratos, D. S., Stefanski, C. D., Caksa, S., Kitterman, E. L., Heilizer, J. S., Chervoneva, I., Fernandes‐Alnemri, T., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0444 · Cited by 6
Self-citationZhou, T. Y., Qian, K., Li, Y.-Y., Cai, W.-K., Yin, S., Wang, P., & He, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.951480 · Cited by 6
Self-citationA Novel Defined Pyroptosis-Related Gene Signature for Predicting the Prognosis of Endometrial Cancer
Liu, S., Zeng, C., Lv, H., Zhang, Y., Xiong, H., & Tang, H. (2022) · Disease Markers · doi:10.1155/2022/7570494 · Cited by 6
Lv, L., Zhang, Y., Kong, R., Wang, C., Wang, X., & Zhou, X. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05018-0 · Cited by 6
Li-hua, Z., Yang, J. J. J., Zhang, Y., Li, Y., Lin, W.-R., & Liu, W. (2024) · World Journal of Clinical Oncology · doi:10.5306/wjco.v15.i2.329 · Cited by 7
Zhou, T., Wang, T., Zeng, K., Qin, R., Jin, Y., Chen, P., & Ju, G. (2022) · Gene · doi:10.1016/j.gene.2022.146243 · Cited by 6
Wan, Q., Wei, R., Wei, X., & Deng, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.998454 · Cited by 6
Huang, X., Yang, W., Hu, X., Li, P., Dong, J., & Li, L. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102454 · Cited by 5
“Targeting pyroptosis to enhance antitumor immunity and regulate TIME is a new avenue for cancer therapy [31 – 33].”
Li, Z., Xia, Z., Yu, Y., Cai, L., Jian, W., Wang, T., Xue, W., Wang, X., Wang, B., Zhang, P., et al. (2022) · BMC Medical Genomics · doi:10.1186/s12920-022-01339-0 · Cited by 5
“These findings may result from many complex factors driving the difference in gene expression between disease and healthy tissues, particularly levels of genes and PRGs linked to inflammation, such as the proportion of infiltrated immune cells and the differentiation of ccRCC [50, 51].”
BackgroundWang, Y., Huang, D., Song, T., Qi, X., Li, M., Zhang, H., Liu, Y., & Yang, M. W. (2022) · Medical Oncology · doi:10.1007/s12032-022-01878-7 · Cited by 5
“small molecular inhibitors with GSDME cleavage prompted a more effective antitumor-immune response [28, 29].”
Establishment and Systematic Evaluation of Gastric Cancer Classification Model Based on Pyroptosis
Kadasah, S. F. (2022) · Diagnostics · doi:10.3390/diagnostics12112858 · Cited by 5
“Besides, pyroptosis was illustrated to regulate the tumor immune microenvironment via the BRAF and MEK inhibitors [13].”
BackgroundShi, H., Yao, H., Zhou, Y., Wu, G., Li, K., Tang, L., Chen, Y., Wang, D., & Jin, W. (2024) · Translational Cancer Research · doi:10.21037/tcr-24-683 · Cited by 5
“Recently, several studies have found that pyroptosis can affect tumorigenesis, cancer progression, and metastasis (14,15).”
Therapeutic connections between pyroptosis and paclitaxel in anti-tumor effects: an updated review
Song, S., Wang, J., Ouyang, X., Huang, R., Wang, F., Xie, J., Chen, Q., & Hu, D. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04036-8 · Cited by 5
“Furthermore, the absence of GSDME is likely to increase the risk of tumor regrowth, reduce the number of activated dendritic cells, and diminish the infiltration of tumor-associated T cells (Erkes et al. 2020), suggesting that GSDME inactivation may enable cancer cells to evade immune attack.”
Sander, C., Rush, E. A., Shi, J. R., Arantes, L. M. R. B., Tesi, R. J., Ross, M. A., Calderon, M. J., Watkins, S. C., Kirkwood, J. M., Ferris, R. L., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03538-w · Cited by 5
Xu, J., Xia, Q., Sun, J., Liu, C., Lu, J., Xu, M., An, Y., Xun, Y., Liu, Z., Hu, J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-44700-8 · Cited by 5
“Results from former analyses indicated that PRGs played essential part in immunoregulation and pyrop-tosis was also reported to be accompanied by immune reaction, especially alterations in tumor immune microenvironment 15 .”
ResultChen, W., Zhuang, X., Chen, W., Cai, Y., 朱冠保, Wang, P., & Tu, J. (2024) · Open Medicine · doi:10.1515/med-2023-0886 · Cited by 5
“Emerging evidence unveils the possible association between pyroptosis and the tumor immune microenvironment [51,52].”
BackgroundMa, S., Wang, F., Wang, N., Jin, J., Yan, X., Wang, L., Zheng, X., Hu, S., & Du, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.893160 · Cited by 5
“, 2020), “warm tumor” corresponds to immune activation and infiltration (Erkes et al., 2020).”
BackgroundXu, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.942765 · Cited by 5
“GSEME-deficient melanoma exhibited defective HMGB1 release, decreased T cells and elevated dendritic cell infiltration (27).”
BackgroundJu, A., Tang, J., Chen, S., Fu, Y., & Luo, Y. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.17.440259 · Cited by 5
Wu, S., Wang, B., Li, H., Wang, H., Du, S., Huang, X., Fan, Y., Gao, Y., Gu, L., Huang, Q., et al. (2026) · Oncogene · doi:10.1038/s41388-025-03671-y · Cited by 4
“Numerous evidence have demonstrated the signi fi cant impact of pyroptosis on the tumor microenvironment (TME), immune cell recruitment and function, as well as tumor growth [21 – 24].”
Yu, H., Gong, M., Qi, J., Zhao, C., Niu, W., Sun, S., Li, S., Hong, B., Qian, J., Wang, H., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09982-7 · Cited by 4
“Small molecule inhibitors of kinases such as MEK, BRAF, EGFR, ALK, and KRAS promoted GSDME cleavage by CASP3 and resulted in lung cancer and melanoma regression [58, 59].”
Li, P., Wang, S., Wan, H., Huang, Y., Yin, K., Sun, K., Jin, H., & Wang, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1258475 · Cited by 4
Lu, Y., Lin, B., Chai, S., Wang, H., Zhou, J., Hu, J., Du, Y., Zhao, C., & Wu, L. (2024) · Materials Today Nano · doi:10.1016/j.mtnano.2024.100492 · Cited by 4
Ren, X., Yu, Q., Pan, Y., Li, F., Yang, Y., & Tian, Q. (2024) · Molecular & Cellular Toxicology · doi:10.1007/s13273-024-00473-3 · Cited by 4
“A recent study showed that pyroptotic cell death of cancer cells promotes activation of dendritic cells and T-cell infiltration, and enhances antitumor immune response through the release of high mobility group protein B1 (Erkes et al. 2020).”
Pyroptosis: A promising target for lung cancer therapy
Zhou, W., Zhao, L., Wang, H., Liu, X., Liu, Y., Xu, K., Yu, H., Suda, K., & He, Y. (2023) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2023.03.001 · Cited by 4
“69 These findings indicate that therapies that activate pyroptosis might be a potential strategy to enhance efficacy and overcome resistance during targeted therapy.”
Targeting SNRPE to Induce Pyroptosis Enhances Antitumor Immunity in Breast Cancer
Ji, Z., Wang, Z., Guo, X., Li, J., Cai, Y., Xiong, Y., Zheng, S. G., & Li, K. (2025) · International Journal of Medical Sciences · doi:10.7150/ijms.109171 · Cited by 3
“Emerging evidence has indicated that immune reactivation is a prerequisite for achieving successful tumor eradication[16, 18, 33].”
Ansari, S. A., Mohanty, S., Mohapatra, P., Datta, S., Swain, M., Rath, R., Muduly, D. K., Majumdar, S., Swain, R. K., Raghav, S. K., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03148-5 · Cited by 3
“A kinome-wide screening was performed using a lentiviral sgRNA library (LentiArray ™ Human Kinase CRISPR Library, Thermo Fisher Scienti fi c, Cat No# M3775) that knocks out 840 kinase and kinase-related genes individually, with a total number of 3214 sgRNA constructs.”
Evolution of a melanoma that escapes allogeneic rejection
Rokan, A., Diniz, M. O., Heras, J. I. D. L., Hall, C., Noorsaeed, S., Bennett, C. L., Secrier, M., Kassiotis, G., & Fassati, A. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116288 · Cited by 3
“19 Furthermore, these cells are clinically relevant because genetic mutations in PTEN and BRAF are present in 50% of human melanomas, 70%–88% of which are BrafV600E.”
Dai, H. (2025) · Clinical Cancer Bulletin · doi:10.1007/s44272-025-00047-x · Cited by 3
Dighe, S., & Jain, S. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104521 · Cited by 3
Wu, D., Zhang, Y., Guo, Y., & Dong, Z. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117587 · Cited by 3
宋崇辉, 全英蘭, Shan, Y., Chen, Y., Du, J., Li, K., & Li, N. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1735908 · Cited by 3
“Its dynamic balance directly participates in regulating the tumor progression process and has a decisive impact on clinical outcomes (29, 30).”
Exploiting immunogenic cell death to promote antitumor immunity
Raffi, G. C., Wang, S., Wang, L., & Bernards, R. (2026) · Trends in Immunology · doi:10.1016/j.it.2026.03.006 · Cited by 3
Liu, L., Chen, C., Tu, G., Peng, Y., Shen, M., Xu, Y., & Liu, S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.821727 · Cited by 3
“Previous studies have confirmed that the effects of proinflammatory PR are caused by the regulation of the tumor immune microenvironment (Erkes et al., 2020), and we found that GSDMD defective expression was associated with a significantly decreased number and activity of CD8 + T lymphocytes (Xi et al.”
BackgroundJanka, E. A., Szabó, I. L., Kollár, S., Toka-Farkas, T., Ványai, B., Várvölgyi, T., Kapitány, A., Shabu, H., Szegedi, A., & Emri, G. (2024) · Cancers · doi:10.3390/cancers16172981 · Cited by 3
“A correlation between clinical outcome and antitumor immunity has been demonstrated in both BRAF + MEK inhibitor-treated and anti-PD-1-treated metastatic melanoma patients [13,39,56].”
BackgroundLin, Z., Xu, Y., Zhang, X., Wan, J., Zheng, T., Chen, H., Chen, S., & Liu, T. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s335073 · Cited by 3
“BRAF and MEK inhibitors could induce GSDME-dependent pyroptosis to modulate tumor immune microenvironment, and BRAF and MEK inhibitors resistant melanoma cells displayed the loss of GSDME cleavage and pyroptosis, thus highlighting the role of GSDME-dependent pyroptosis in anti-tumor immune response.(37) In addition, v…”
BackgroundWu, D., Fan, W., Zhang, Z., Jianming, T., Zhang, C., Chen, W., Qin, N., & Zheng, Y. (2022) · Journal of Oncology · doi:10.1155/2022/1434565 · Cited by 3
Silver nanoparticles as proapoptotic drugs: pharmacological basis in non-metastatic skin melanoma
Novelles, M. D. C. T., Brown, T. S. P., Feliciano, D. N., Travieso, A. G., & Hernández, I. R. (2022) · Pharmacy & Pharmacology International Journal · doi:10.15406/ppij.2022.10.00366 · Cited by 3
An Anionic Cathelicidin Exerts Antimelanoma Effects in Mice by Promoting Pyroptosis
Chen, Q., Feng, G., Shen, Y., Li, X., Pei, Q., Wang, H., Li, T. X., Cao, Y., Wu, J., Yang, H., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00281 · Cited by 2
Yao, S., Chen, S., Wan, S., Wang, A., Liang, Z., Liu, X., Gao, Y., & Cai, H. (2025) · Cancer Medicine · doi:10.1002/cam4.71278 · Cited by 2
From mechanisms to markers: role of pyroptosis in revolutionizing thyroid cancer care
Wang, N., Chen, Y., Luo, G., & Luo, D. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02741-0 · Cited by 3
Kang, H., Wu, S., Gong, H., & Li, F. (2026) · Translational Cancer Research · doi:10.21037/tcr-2025-1882 · Cited by 2
“They enhance tumor antigen presentation, promote T cell infiltration, and reduce immunosuppressive factors, collectively converting immunologically “cold” tumors into “hot” ones (168).”
The double-edged sword of pyroptosis targeting in cancer therapy
Mao, S., Lei, T., Shi, F., Xu, J., Zhuang, W., Lu, J., Dong, X., & Yang, H. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118788 · Cited by 2
Jin, T., Dong, L., Kai, W., Yu, Z., Yu, G., & Liu, W. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71110 · Cited by 2
Wang, Y., CHEN, J., Zhang, X., Ji, Z., Zhang, N., Li, N., Zhang, X., Zhao, S., Li, C., Shi, K., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04343-z · Cited by 2
“Combining these approaches with immune checkpoint inhibitors (ICIs) further enhances antitumor immunity [94, 108].”
Cell death pathways and targeting therapeutics in cancer therapy
Zhan, B., Zhang, H.-L., Xiao, Y., Zhong, W.-Q., Guo, Y., Shan, J., Tang, J.-H., Zhu, X.-F., & Deng, R. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01803-y · Cited by 2
“In BRAFi + MEKi-resistant disease, a lack of pyroptosis markers and decreased intratumoral T-cell in fi ltration was observed, suggesting that BRAFi + MEKi-induced pyroptosis is crucial for enhancing the immune response and fi ghting against tumors [108].”
Wei, X., Jiang, Y., Li, Z., Hu, J., Chenwu, F., Li, F., Song, M., He, Y., & Wang, J. (2026) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2026.218178 · Cited by 2
Boaru, D. L., Castro-Martinez, P. D., García-Montero, C., Fraile‐Μartinez, O., Alhaddadin, M. N. M., Barrena-Blázquez, S., López-González, L., Tasende, C., Hurtado, R. A., Giménez, T. R., et al. (2026) · MedComm · doi:10.1002/mco2.70844 · Cited by 2
“Experimentally, combined targeted therapies (BRAF + MEK inhibitors) have been shown to trigger GSDME-dependent pyrop-tosis in melanoma, linking targeted therapy responses to immune activation [ 370 ].”
Tang, D., Lei, J. H., Lin, S., Zhou, J., Wu, X., Qiao, Y., Sun, H., Chen, Q., Xing, F., Wang, X., et al. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108396 · Cited by 2
He, J., Jia, J., Lei, J., Yu, J., Zhou, W., & Zhang, M. (2023) · Cancer Biomarkers · doi:10.3233/cbm-220362 · Cited by 2
“An increasing number of studies have demonstrated the complex crosstalk be-tween the TME and pyroptosis [17,18].”
Zeng, J., Zhu, P., Tang, Y., Zhang, C., Ye, C., Cheng, S., Tian, K., Yang, B., Zeng, W., Liu, Y., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-43023-y · Cited by 2
Identification of a Novel Pyroptosis-Related lncRNAs Prognosis Model and Subtypes in Ovarian Cancer
Xie, X., Hu, X., Liu, D.-X., Wang, W., & Hua, T. (2025) · Phenomics · doi:10.1007/s43657-024-00173-x · Cited by 2
“There was emerging evidence that crosstalk between pyroptosis and tumor microenvironment (TME) (Erkes et al. 2020 ).”
Huang, B., Su, W., & Yu, D. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1081418 · Cited by 2
“Over the past years, the combination of immune therapy (anti-PD-1, anti-CTLA-4) and target therapy (BRAF inhibitor) has achieved an impressive improvement of the patients’ survival (Erkes et al., 2020).”
BackgroundJiang, P., Fan, J., Huang, S., Liu, L., Bai, M., Sun, Q., Shen, J., Zhang, N., Liu, D., Zhou, N., et al. (2023) · PeerJ · doi:10.7717/peerj.16631 · Cited by 2
Sun, L., Liu, Y., Zhou, H., Zhang, M., Cao, X., & Zhang, J. (2022) · Research Square · doi:10.21203/rs.3.rs-2349164/v1 · Cited by 2
Reframing cell death: Unveiling interactions and synergistic mechanisms in tumor immunity
Jiang, R., & Cai, P. (2026) · Current Proteomics · doi:10.1016/j.curpro.2026.100078 · Cited by 2
Characteristics of two different immune infiltrating pyroptosis subtypes in ischemic stroke
Xiao, Y., Wang, Z., Xin, Y., Wang, X., & Dong, Z. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36349 · Cited by 1
Tu, S., Xi, J., Bu, X., Zhang, Q., Liao, S., Zhu, X., Guo, Y., & Sha, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-96158-5 · Cited by 2
“Research has shown that excessive pyroptotic cell death significantly promotes cardiovascular, autoimmune, and other diseases, as well as various tumors 21–23 .”
Kim, J., Seo, H., & Kim, D. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.217375 · Cited by 1
Harnessing pyroptosis to restrain melanoma through aripiprazole
Chang, Y.-T., Lin, I.-H., Shieh, J., Lan, T., Syu, J., Huang, S. R., & Hou, P. (2026) · APOPTOSIS · doi:10.1007/s10495-025-02223-9 · Cited by 1
“Several combination regimens, including the FDA-approved BRAF + MEK inhibitor cocktail for BRAF-mutant melanoma and the metformin + doxorubicin combination in preclinical models, have demonstrated tumor control in part to due to pyrop-tosis induction [20–22 ].”
Targeting methionine-induced pyroptosis enhances anti-tumor immunity
Lei, M., Zhu, W., Wang, C., Zhang, F., Li, M., Zhang, Y., Qu, J., Luo, Z., Li, J., Li, Z.-X., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3149-4 · Cited by 1
Wang, Y., Mei, M., Wang, J., Wei, L., Zhang, M., & Zhang, M. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102747 · Cited by 1
“These soluble mediators collectively drive dendritic cell maturation, foster M1 macrophage polarization, and orchestrate the infiltration and activation of cytotoxic CD8 + T cells within the tumor microenvironment [43,44].”
Oridonin and ponicidin induce GSDME-mediated pyroptosis in pancreatic ductal adenocarcinoma
Liu, X., Fu, J., He, T., Yang, R., Ma, D., & Chen, J. (2026) · Journal of Chromatography B · doi:10.1016/j.jchromb.2026.125145 · Cited by 1
Du, J., Yang, Y., Zhao, M., Zhang, H., Li, X., Qu, D., Wang, J., Wang, X., Yi, X., Ma, J. X., et al. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01767-w · Cited by 1
Li, C., Lin, C., & Xie, X. (2022) · Journal of Oncology · doi:10.1155/2022/6609297 · Cited by 1
“Studies have shown that the efficacy of ICI can be substantially improved when combined with irradiation-induced or chemotherapy-induced tumor pyroptotic cell death [15, 18, 25, 26].”
BackgroundA novel pyroptosis-related gene signature for predicting laryngeal carcinoma prognosis.
Zhang, H., Wang, L., Yin, Z., Ji, L., & Guo, Y. (2022) · PubMed · Cited by 1
yunshan, W., Ren, Y., Feng, M., Liu, X., Hao, X., Li, J., Li, P., Gao, J., Qi, Q., Du, L., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1046804/v1 · Cited by 1
Yang, W., Huang, X., Zhang, Y., Tian, Y., Pan, T., Guo, Y. C., Dong, J., & Li, L. (2022) · Research Square · doi:10.21203/rs.3.rs-2185352/v1 · Cited by 1
Peptide aggregation-induced immunogenic cell death in a breast cancer spheroid modelPreprint
Gunay, G., Maier, K. N., Hamsici, S., Carvalho, F., Timog, T. A., & Acar, H. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.31.565012 · Cited by 1
“Inspired by the structures of transmembrane pore-forming proteins 21–23 , we utilized our molecular framework 19 and designed a pair of oppositely charged peptides [II] that penetrate cells, aggregate, and induce stress and ICD 18,24 .”
MethodMcKenzie, B., Puisségur, M.-P., Demeersseman, L., Rodriguez, F., Cini, E., Jainarayanan, A., Widdess, M. A., Staton, C. C., Chen, L., Sibaud, V., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.24.595698 · Cited by 1
Yang, J., Li, Y., Wan, K., Li-jun, Y., Feng, F., Wang, W., Zhang, L., & Li, W. (2024) · Research Square · doi:10.21203/rs.3.rs-4455036/v1 · Cited by 1
Xu, J., Wang, X., Jiang, H., Chen, Y., Wang, R., & Shu, Y. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001070
“[9] Therapeutic ef fi cacy MEKi treatment in vivo depends on an intact immune system.”
Jin, Y., & Xue-song, B. (2021) · Research Square · doi:10.21203/rs.3.rs-1020197/v1
Wang, G., Gao, H., Chen, J., Dai, S., Gao, Y., Yin, L., Jiang, K., Miao, Y., & Lu, Z. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4017385
Metadata
- Authors
- Erkes, D. A., Cai, W., Sanchez, I. M., Purwin, T. J., Rogers, C., Field, C. O., Berger, A. C., Hartsough, E. J., Rodeck, U., Alnemri, E. S., & Aplin, A. E.
- Affiliations
- Thomas Jefferson University (US)
- Corresponding author
- Alnemri, Emad S.
- Aplin, Andrew E.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2020-02-01
- Volume
- 10
- Issue
- 2
- Pages
- 254-269
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC7007378
- OpenAlex
- W2993434511
- Cited by
- 459
- References
- 67
- Citations by year
- 2026: 38 · 2025: 52 · 2024: 78 · 2023: 84 · 2022: 114 · 2021: 72 · 2020: 21
- FWCI
- 18.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Cancer Discovery (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- HHS | NIH | National Cancer Institute (CA196278, CA160495, CA182635, CA207855)
- Dr. Ralph and Marian Falk Medical Research Trust (N/A)
- HHS | National Institutes of Health (AR055398, AR074564)
- U.S. Department of Defense (PC150650)
- American Cancer Society (PF-18-096-01-LIB)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- BRAF inhibitors, MEK inhibitors, pyroptosis, gasdermin E, HMGB1, tumor immune microenvironment, antitumor immunity, T cell infiltration, dendritic cells, drug resistance, salvage therapy, targeted therapy
- MeSH terms
- Pyroptosis, Proof of Concept Study, Immune Checkpoint Inhibitors, Animals, Antineoplastic Combined Chemotherapy Protocols, Dendritic Cells, Disease Models, Animal, Female, Humans, Male, Melanoma, Mutation, Skin Neoplasms, Drug Resistance, Neoplasm, Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.